Tag: cancer cachexia market

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer cachexia market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Cancer Cachexia Market be in 2030 compared with 2026?

The cancer cachexia market has experienced robust growth in recent times. This market is projected to expand from $2.6 billion in 2025 to $2.75 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. Historically, this expansion can be ascribed to a rising occurrence of late-stage cancer diagnoses, enhanced clinical understanding of cachexia management, an expanding distribution network through hospital pharmacies, the initial uptake of anabolic agents, and a broader provision of supportive oncology care.

The cancer cachexia market size is projected to experience substantial growth in the coming years, with its value expected to reach $3.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. This expansion during the forecast period is fueled by an escalating demand for personalized cachexia treatments, increased clinical research into innovative mechanisms, the broadening of outpatient oncology services, the expanding application of digital patient monitoring tools, and a heightened emphasis on quality-of-life outcomes. Prominent trends anticipated in the forecast period include the increasing utilization of combination drug regimens, a growing focus on muscle preservation therapies, the rising adoption of nutritional supplementation strategies, the proliferation of anti-inflammatory cachexia treatments, and more advanced monitoring of cachexia progression.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

What Drivers Are Guiding Growth Patterns In The Cancer Cachexia Market?

The rising incidence of cancer is projected to fuel the growth of the cancer cachexia market in the coming period. Cancer is a medical condition where abnormal cells multiply without control in the body, forming tumors and interfering with typical bodily processes. Various elements contribute to the increasing instances of cancer, such as shifts in lifestyle, environmental factors, an aging demographic, genetic susceptibilities, improvements in diagnostic methods leading to quicker identification, and enhanced awareness encouraging more people to seek medical attention. Breakthroughs in medical technology and a more comprehensive understanding of cancer and its complexities are leading to more frequent diagnoses and reporting of cancer cachexia. Healthcare practitioners are improving their capability to identify cachexia symptoms, which supports earlier interventions and the commencement of treatment. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, it was estimated that 165,000 Australians were newly diagnosed with cancer in 2023, which is more than 450 cases daily, and males made up about 55% of these diagnoses. Hence, the growing prevalence of cancer is serving as a primary driver for the expansion of the cancer cachexia market.

How Is The Cancer Cachexia Market Divided Into Segments?

The cancer cachexia market covered in this report is segmented –

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate

2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs

What Industry Trends Are Transforming The Cancer Cachexia Market?

Prominent companies operating within the cancer cachexia market are innovating medications, such as monoclonal antibodies for cachexia, to create targeted treatments for cancer cachexia, aspiring to enhance body weight, muscle mass, and the overall quality of life for those afflicted. A monoclonal antibody specifically for cachexia operates by targeting and inhibiting the factors that lead to muscle and weight loss. For example, in September 2024, Pfizer Inc., a pharmaceutical company based in the US, reported positive findings from its Phase 2 study of Ponsegromab, a monoclonal antibody designed to target GDF-15, in individuals with cancer cachexia. The study illustrated a notable increase in body weight and enhancements in muscle mass, appetite, and physical activity, with the 400 mg dose demonstrating the most compelling outcomes. Building on these encouraging discoveries, Pfizer intends to launch registration-enabling studies in 2025 to further examine Ponsegromab’s capability for treating cancer cachexia.

Which Leading Companies Dominate The Cancer Cachexia Market Share?

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

How Does The Cancer Cachexia Market Perform Across Major Global Regions?

North America was the largest region in the cancer cachexia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer Cachexia Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Browse Through More Reports Similar to the Global Cancer Cachexia Market 2026, By The Business Research Company

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Chemotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Cancer Cachexia Market?

In recent years, the market size for cancer cachexia has seen substantial growth. It is set to expand from a valuation of $2.47 billion in 2024 to $2.6 billion in 2025, portraying a compound annual growth rate (CAGR) of 5.3%. Factors such as enhanced knowledge of cancer biology, rising incidences of cancer, a growing elderly population, increased emphasis on patient-oriented care, a broader range of treatment choices, and increased cognizance among healthcare providers were integral to growth observed in the historical period.

The market for cancer cachexia is anticipated to experience robust expansion in the upcoming years, with expectations to reach $3.21 billion by 2029, rising at a compound annual growth rate (CAGR) of 5.5%. The predicted growth during the forecast period can be credited to the growing awareness about cachexia management, increasing geriatric population, the adoption of innovative treatment protocols, amplified health expenditure, and supportive initiatives by the government. Key trends projected for the forecast period include escalated research and development endeavors, augmentation of therapeutic solutions, enhancements in diagnosis rates, the uptake of pioneering treatment modalities, and advancements in accommodative care techniques.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

What Drivers Are Accelerating Expansion Of The Cancer Cachexia Market?

The growth of the cancer cachexia market is predicted to be driven by the rising incidences of cancer. This disease is characterized by abnormal cell proliferation, leading to tumor formation and interference with regular bodily activities. Factors contributing to cancer cases include lifestyle shifts, environmental influences, aging demographics, genetic susceptibility, superior diagnostics resulting in early detection, and heightened awareness, encouraging more individuals to seek medical consultation. Progress in medical technology and a deeper comprehension of cancer and its complications have led to greater diagnosis and recording of cancer cachexia. Healthcare workers are enhancing their proficiency in recognising cachexia symptoms, enabling prompt intervention and initiation of treatment. For example, in December 2023, the Australian Bureau of Statistics reported that approximately 1.8% of Australians or 456,200 individuals had been diagnosed with cancer in the previous year. Additionally, the National Cancer Institute estimated in May 2024, that there would be around 2,001,140 new cancer cases and 611,720 cancer-related deaths in the U.S. in 2024. In 2022, approximately 20 million fresh cases and 9.7 million deaths related to cancer were noted globally. By 2040, it is anticipated that the annual number of new cancer cases will increase to 29.9 million, and deaths due to cancer will reach 15.3 million. Consequently, the surge in cancer incidence is propelling the expansion of the cancer cachexia market.

What Are The Key Segment Trends Observed In The Cancer Cachexia Market?

The cancer cachexiamarket covered in this report is segmented –

1) By Therapeutics: Progestogens; Corticosteroids; Combination Therapies; Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators; Weight Loss Stabilizers; Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores; Retail Pharmacy Stores; Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate; Medroxyprogesterone Acetate; Hydroxyprogesterone Caproate

2) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids; Progestogens + Anabolic Agents; Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents; Appetite Stimulants; Anti-inflammatory Drugs; Nutritional Supplements

What Strategic Shifts And Innovations Are Influencing The Cancer Cachexia Market?

Leading businesses in the cancer cachexia market are revolutionizing their approach by innovating new treatments such as monoclonal antibodies specifically for cachexia. Their goal is to create a focused solution for cancer cachexia to enhance body weight, muscle mass, and consequently, the overall life quality of the patients affected. These monoclonal antibodies specially designed for cachexia aim to counteract determinants that result in muscle deterioration and weight loss. For instance, US-based pharmaceutical giant, Pfizer Inc., declared the successful outcomes of their Phase 2 trial for Ponsegromab, a monoclonal antibody that targets GDF-15, in patients affected by cancer cachexia in September 2024. The study exhibited a notable rise in body weight, muscle mass, appetite, and physical activity levels, with the 400 mg dosage delivering the most powerful results. Given these encouraging results, Pfizer is planning to start initial enrollment studies in 2025 to further explore Ponsegromab’s potential in cancer cachexia treatment.

Who Are The Major Stakeholders Operating In The Cancer Cachexia Market?

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

What Regional Factors Are Accelerating Growth In The Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Browse Through More Reports Similar to the Global Cancer Cachexia Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Breast Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Bone Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bone-cancer-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Cancer Cachexia Market Expected To Expand Between 2025 And 2029?

The cancer cachexia market size has shown robust growth over recent years. The market is anticipated to increase from $2.47 billion in 2024 to $2.6 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.3%. The historical market expansion is attributable to several factors, including enhanced comprehension of cancer biology, the widespread incidence of cancer, a growing elderly population, an increased emphasis on patient-focused care, a wider array of treatment options, and escalating awareness among healthcare professionals.

The cancer cachexia market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $3.21 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast period is fueled by several factors, including heightened awareness regarding cachexia management, an increase in the elderly population, the increasing integration of innovative therapeutic methods, a rise in healthcare spending, and supportive governmental policies. Prominent developments expected within this period encompass intensified research and development activities, a broader array of treatment choices, enhanced diagnostic accuracy, the implementation of new treatment approaches, and progress in supportive care strategies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

Which Drivers Are Supporting Growth Of The Cancer Cachexia Market?

The expanding occurrence of cancer is anticipated to fuel the expansion of the cancer cachexia market in the coming period. Cancer is defined as a disease characterized by the uninhibited multiplication of abnormal cells within the body, leading to tumor formation and interference with regular physiological functions. The rise in cancer cases stems from multiple contributing elements, such as shifts in lifestyle, environmental influences, an aging demographic, inherited susceptibility, enhanced diagnostic techniques enabling earlier identification, and greater public awareness encouraging individuals to seek medical advice. Progress in medical technology, alongside a deeper comprehension of cancer and its associated complications, is leading to a higher frequency of cancer cachexia diagnoses and reported cases. Medical practitioners are becoming more proficient at recognizing cachexia symptoms, which aids in commencing interventions and treatments sooner. For example, data from December 2023 by the Australian Bureau of Statistics, an Australian government body for national statistics, indicated that approximately 1.8% of Australia’s population, equivalent to 456,200 people, had cancer in 2022. Additionally, in May 2024, the National Cancer Institute, a U.S. federal government agency, projected that in 2024, around 2,001,140 new cancer diagnoses would occur in the U.S., with an anticipated 611,720 fatalities due to the illness. Globally, 2022 saw nearly 20 million new cancer occurrences and 9.7 million deaths linked to cancer. Projections suggest that by 2040, the annual count of new cancer cases will climb to 29.9 million, and cancer-related deaths will reach 15.3 million. Consequently, the rising incidence of cancer is a key factor propelling the expansion of the cancer cachexia market.

What Are The Major Segments Identified In The Cancer Cachexia Market?

The cancer cachexiamarket covered in this report is segmented –

1) By Therapeutics: Progestogens; Corticosteroids; Combination Therapies; Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators; Weight Loss Stabilizers; Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores; Retail Pharmacy Stores; Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate; Medroxyprogesterone Acetate; Hydroxyprogesterone Caproate

2) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids; Progestogens + Anabolic Agents; Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents; Appetite Stimulants; Anti-inflammatory Drugs; Nutritional Supplements

What Trends Are Expected To Drive The Cancer Cachexia Market?

Leading companies in the cancer cachexia market are actively developing innovative medications, such as monoclonal antibodies for cachexia, to provide a targeted treatment for cancer cachexia, aiming to enhance body weight, muscle mass, and overall quality of life for affected individuals. A monoclonal antibody for cachexia works by targeting and inhibiting the factors that cause muscle and weight loss. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical company, announced the positive results from its Phase 2 study of Ponsegromab, a monoclonal antibody designed to target GDF-15, in patients with cancer cachexia. The study showcased a significant increase in body weight and improvements in muscle mass, appetite, and physical activity, with the 400 mg dose demonstrating the most robust outcomes. Based on these promising findings, Pfizer intends to initiate registration-enabling studies in 2025 to further evaluate Ponsegromab’s potential for treating cancer cachexia.

Which Key Players Are Driving Competition In The Cancer Cachexia Market?

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cancer Cachexia Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Browse Through More Reports Similar to the Global Cancer Cachexia Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Breast Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Bone Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bone-cancer-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What is the Projected CAGR for the Cancer Cachexia Market Size from 2025 to 2034?#_x000D_

In the past few years, the market size for cancer cachexia has seen robust growth. The market, which was worth $2.47 billion in 2024, is expected to rise to $2.6 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 5.3%. This growth in the earlier period can be credited to heightened understanding of the biology of cancer, wide prevalence of the disease, increasing aged population, enhanced emphasis on patient-oriented care, wider range of treatment options, and increased consciousness among providers of healthcare services._x000D_

_x000D_

The market size of cancer cachexia is anticipated to witness significant expansion in the coming years. It is projected to increase to$3.21 billion in 2029 with a compound annual growth rate (CAGR) of 5.5%.” Factors contributing to this growth for the forecast period include heightened awareness regarding cachexia management, growing elderly populace, an increase in the uptake of innovative therapeutic strategies, escalating healthcare spending, and supportive governmental initiatives. The forecast period will also see key trends such as heightened research and development activities, broadening therapeutic alternatives, improved detection rates, adoption of new treatment methods, and advancements in supportive care approaches._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp_x000D_

_x000D_

#What Are the Major Market Drivers Behind the Rising Adoption of Cancer Cachexia Market?#_x000D_

The cancer cachexia market’s expansion is predicted to be fueled by the escalating occurrence of cancer. Cancer is a condition characterized by uncontrolled growth of abnormal cells in the body, which results in tumor formation and disrupts ordinary bodily processes. Multiple factors are believed to contribute to the incidence of cancer, such as changes in lifestyle, environmental factors, an aging population, genetic susceptibility, enhanced diagnostic techniques for early detection, and heightened awareness leading more individuals to seek medical help. Progress in medical technology and a deeper comprehension of cancer and its complications are leading to more frequent cancer cachexia diagnoses and reports. Healthcare practitioners are honing their skills to spot symptoms of cachexia, which allows for prompt interventions and commencement of treatment. For example, data from the Australian Bureau of Statistics in December 2023 showed that around 1.8% of the population, equaling approximately 456,200 people, were reported to have cancer in Australia in 2022. Additionally, according to the National Cancer Institute in the United States in May 2024, it is anticipated that in 2024, around 2,001,140 new cancer instances will be identified in the U.S., with an expected 611,720 cancer-related deaths. In 2022, almost 20 million new cases and 9.7 million cancer-related deaths were reported globally. By 2040, the projected new cancer cases annually are expected to surge to 29.9 million, with cancer-related deaths reaching 15.3 million. Consequently, the escalating incidence of cancer is stimulating the cancer cachexia market’s growth._x000D_

_x000D_

#Which Key Market Segments Comprise the Cancer Cachexia Market and Drive Its Revenue Growth?#_x000D_

The cancer cachexiamarket covered in this report is segmented – _x000D_

_x000D_

1) By Therapeutics: Progestogens; Corticosteroids; Combination Therapies; Other Therapeutics_x000D_

2) By Mechanism Of Action: Appetite Stimulators; Weight Loss Stabilizers; Other Mechanisms Of Actions_x000D_

3) By Distribution Channel: Hospital Stores; Retail Pharmacy Stores; Online Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By Progestogens: Megestrol Acetate; Medroxyprogesterone Acetate; Hydroxyprogesterone Caproate _x000D_

2) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone _x000D_

3) By Combination Therapies: Progestogens + Corticosteroids; Progestogens + Anabolic Agents; Corticosteroids + Anabolic Agents _x000D_

4) By Other Therapeutics: Anabolic Agents; Appetite Stimulants; Anti-inflammatory Drugs; Nutritional Supplements_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Cancer Cachexia Market Expansion Across the Globe?#_x000D_

North America was the largest region in the cancer cachexia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Cancer Cachexia Market?#_x000D_

Leading companies in the cancer cachexia market are focusing on the creation of novel medications, including monoclonal antibodies for cachexia, with the goal of offering targeted therapies for this condition. This approach aims to enhance body weight, muscle mass, and overall life quality in patients affected by cachexia. The monoclonal antibodies aim to block factors promoting muscle and weight loss. For example, Pfizer Inc., an American pharmaceutical firm, revealed positive outcomes from its Phase 2 trial for Ponsegromab, a monoclonal antibody targeting GDF-15, for cachexia patients in September 2024. The trial demonstrated significant improvements in body weight, muscle mass, appetite, and physical activity levels, with the 400 mg dosage showing the best results. Encouraged by these optimistic results, Pfizer intends to launch studies that could potentially pave the way for the registration of Ponsegromab in 2025 to further explore its potential in treating cancer cachexia._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report_x000D_

_x000D_

#How Is the Cancer Cachexia Market Conceptually Defined?#_x000D_

Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. It is a multifactorial condition resulting from a combination of factors such as inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient’s quality of life, impairing their ability to tolerate cancer treatments and reducing their overall survival._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15527_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Cancer Cachexia Market From 2025 To 2029?

In recent times, there has been a robust growth in the cancer cachexia market size. It is projected to rise from $2.47 billion in 2024 to $2.62 billion in 2025, showcasing a compound annual growth rate (CAGR) of 6.4%. The growth over the historic period could be ascribed to enhanced knowledge of cancer biology, rising cancer prevalence, an escalading elderly population, increased emphasis on patient-centered care, wider range of treatment options, and heightened awareness amongst healthcare providers.

What Is the Projected Market Size of the Cancer Cachexia Market?

The market for cancer cachexia is projected to experience robust expansion in the upcoming years, reaching $3.33 billion by 2029 with a 6.2% compound annual growth rate (CAGR). The projected growth within this forecast period may be due to a heightened understanding of cachexia management, a burgeoning aging population, increased acceptance of innovative therapeutic methods, rising healthcare expense, and supportive government policies. Major occurrences predicted for this period encompass escalating research and development activities, broadening therapeutic alternatives, enhanced rates of diagnoses, implementation of groundbreaking treatment modalities, and advancements in support care tactics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

Who are the Major Competitors in the Cancer Cachexia Market Outlook?

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

What Is Fueling Growth in the Cancer Cachexia Market?

The swell in cancer incidences is anticipated to stimulate the expansion of the cancer cachexia market. Cancer encompasses a condition in which abnormal cells grow rampantly in the body, constructing tumors and obstructing ordinary body functions. The rise in cancer cases is credited to various constituents, inclusive of lifestyle alterations, environmental elements, an aging populace, genetic predisposition, refined diagnostic procedures resulting in earlier identification, and heightened awareness, thereby encouraging more individuals to pursue medicinal care. Gains in medical technology and a heightened comprehension of cancer and its complications are contributing to more frequent discoveries and documentation of cancer cachexia. Healthcare practitioners are enhancing their skill to distinguish cachexia symptoms, enabling precocious interventions and the initiation of treatment. For instance, in December 2023, as per the Australian Bureau of Statistics, a government agency based in Australia for national statistics, approximately 1.8% of the populace, or 456,200 people, were stated to have cancer in Australia in 2022. Also, in May 2024, as per the National Cancer Institute, a Federal government agency based in the U.S., in 2024, an expected 2,001,140 new cases of cancer will be diagnosed in the U.S., with predictions of 611,720 deaths from the disease. In 2022, approximately 20 million new cases globally and 9.7 million cancer-related deaths transpired. By 2040, the quantity of new cancer cases yearly is anticipated to jump to 29.9 million and cancer-related deaths to 15.3 million. Consequently, the escalating prevalence of cancer is fueling the growth of the cancer cachexia market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Which Cancer Cachexia Market Segments Are Growing the Fastest?

The cancer cachexia market covered in this report is segmented –

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate, Hydroxyprogesterone Caproate

2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs, Nutritional Supplements

Which Industry Trends Are Shaping the Future of the Cancer Cachexia Market?

Leading firms in the cancer cachexia market are focusing on the creation of novel treatments such as monoclonal antibodies for cachexia, with the goal of producing a precise therapy for cancer cachexia and enhancing the body weight, muscle bulk, and overall life quality of the afflicted patients. A cachexia-specific monoclonal antibody functions by targeting and suppressing factors that contribute to weight and muscle loss. For example, Pfizer Inc., an American pharmaceutical corporation, revealed promising results of its Phase 2 trial for Ponsegromab, a GDF-15-targeting monoclonal antibody, in cancer cachexia patients, in September 2024. This study demonstrated a marked body weight increase and improvements in muscle bulk, appetite, and physical activity levels, with the 400mg dose yielding the most powerful results. Based on these encouraging outcomes, Pfizer intends to commence registration-enabling studies in 2025 to further explore Ponsegromab’s efficacy in treating cancer cachexia.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Which Countries Are Leading the Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15527

This Report Delivers Insight On:

1. How big is the cancer cachexia market, and how is it changing globally?

2. Who are the major companies in the cancer cachexia market, and how are they performing?

3. What are the key opportunities and risks in the cancer cachexia market right now?

4. Which products or customer segments are growing the most in the cancer cachexia market?

5. What factors are helping or slowing down the growth of the cancer cachexia market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cancer cachexia industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Cancer Cachexia Market Size Shifted, And What Is the Outlook Through 2034?

The market size of cancer cachexia has seen significant growth in the past few years. It is projected to increase from $2.47 billion in 2024 to $2.62 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 6.4%. Factors such as enhanced comprehension of cancer biology, increasing cancer occurrence, an amplified aging demographic, an emphasis on individual-centric care, expansion of treatment alternatives, and heightened awareness within the healthcare provider community have all influenced the growth in the historic period.

Predictions suggest a robust expansion in the size of the cancer cachexia market over the coming years. It’s estimated to rise to $3.33 billion in 2029, with a compound annual growth rate (CAGR) of 6.2%. This growth forecast can be linked to an enhanced understanding of cachexia management, an increase in the elderly population, a higher acceptance rate of innovative therapeutic methodologies, an escalation in healthcare costs and beneficial governmental initiatives. Some key trends expected in the projected period include, augmenting efforts in research and development, an increase in therapeutic alternatives, an improvement in diagnosis rates, the acceptance of new treatment methods, and advancements in supportive healthcare strategies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Cancer Cachexia Market?

The cancer cachexia market is anticipated to expand due to the escalating occurrences of cancer. Cancer is a state characterized by the unchecked proliferation of abnormal cells in the body, which leads to tumor formation and interrupts regular bodily functions. Various factors are associated with cancer rates which include lifestyle modifications, environmental influences, an aging demographic, genetic susceptibility, enhanced detection methods resulting in earlier diagnosis, and heightened awareness urging more individuals to seek medical help. Progress in healthcare technology and a deeper comprehension of cancer and its complications have led to an increased diagnosis and reporting of cancer cachexia. Medical professionals are honing their skills in recognizing cachexia indicators, thus paving the way for quicker interventions and treatment initiation. For instance, the Australian Bureau of Statistics revealed in December 2023 that roughly 1.8% of the population or 456,200 individuals had cancer in Australia in 2022. Moreover, according to the National cancer institute in May 2024, it is projected that 2,001,140 new cancer cases will be diagnosed in the US in 2024, with anticipated death rates reaching 611,720. In 2022, close to 20 million new cases and 9.7 million deaths related to cancer occurred globally. By 2040, these numbers are expected to escalate to 29.9 million new cases annually and about 15.3 million deaths. Consequently, the rising prevalence of cancer is the propellant for the expansion of the cancer cachexia market.

Which Segments in the Cancer Cachexia Offer the Most Growth?

The cancer cachexia market covered in this report is segmented –

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate, Hydroxyprogesterone Caproate

2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs, Nutritional Supplements

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

What Are the Fastest-Growing Geographies in the Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Cancer Cachexia Industry?

Leading corporations in the cancer cachexia market are pushing boundaries by creating innovative medicinal solutions such as monoclonal antibodies for cachexia. This targeted treatment is designed to enhance body weight, muscle mass, and the overall life quality of individuals suffering from cancer cachexia. Monoclonal antibodies for cachexia focus on curbing factors resulting in muscle and weight reduction. For instance, Pfizer Inc., an American pharmaceutical giant, reported favorable results in September 2024 for their Phase 2 trial of Ponsegromab. This monoclonal antibody targets GDF-15, commonly found in patients with cancer cachexia. The trial revealed significant improvements in patients’ body weight, muscle mass, appetite, and physical activity, particularly in those administered with the 400 mg dose. Pfizer, encouraged by these positive results, intends to start registration-enabling studies by 2025 to further probe the efficacy of Ponsegromab in treating cancer cachexia.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

What Are the Key Elements That Define the Cancer Cachexia Market?

Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. It is a multifactorial condition resulting from a combination of factors such as inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient’s quality of life, impairing their ability to tolerate cancer treatments and reducing their overall survival.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15527

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model